CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. - Test2 - elhamkhani - TriplyDB

CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease.

CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease.

http://www.wikidata.org/entity/Q35213298

about

CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection Microglia Ontology and Signaling G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs Alzheimer's Disease: Mechanism and Approach to Cell Therapy The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease Fractalkine Signaling and Microglia Functions in the Developing Brain From development to dysfunction: microglia and the complement cascade in CNS homeostasis Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.Microglia development and function IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology Microglia communication: Parallels between aging and Alzheimer's disease The ischemic environment drives microglia and macrophage function Neuroinflammation in Alzheimer's disease Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study Chronic neuroinflammation and cognitive impairment following transient global cerebral ischemia: role of fractalkine/CX3CR1 signaling Central Nervous System: (Immunological) Ivory Tower or Not?Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents.Microglia as a critical player in both developmental and late-life CNS pathologies.Old Maids: Aging and Its Impact on Microglia Function.A novel method for gathering and prioritizing disease candidate genes based on construction of a set of disease-related MeSH® terms.Increased Amyloid Precursor Protein and Tau Expression Manifests as Key Secondary Cell Death in Chronic Traumatic Brain Injury.Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles Modulating neurotoxicity through CX3CL1/CX3CR1 signaling.SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β.Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in Amyotrophic Lateral Sclerosis (ALS)--in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia.Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy The evolving biology of microglia in Alzheimer's disease.Neuronal Cx3cr1 Deficiency Protects against Amyloid β-Induced Neurotoxicity.Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis.The biphasic role of microglia in Alzheimer's disease.Time-dependent effects of CX3CR1 in a mouse model of mild traumatic brain injury Fractalkine signaling in regulation of insulin secretion.When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration?Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice Disruption of Fractalkine Signaling Leads to Microglial Activation and Neuronal Damage in the Diabetic Retina.Microglial malfunction: the third rail in the development of Alzheimer's disease.

P2860

Q26739374-7AAD0722-D5E7-4751-9D4F-C1E7278B89BC Q26742077-89E89EAB-54CB-4293-AFAB-E31D54C7B9FF Q26752403-287328A0-A2DB-4953-87F3-E3F950CB0D1D Q26778149-646D1AFB-68E7-489B-ABEF-9DC58C58716A Q26781815-9BDFA65A-6EFF-48C4-8F44-9EF4681FD246 Q26782935-BE36F201-9DC7-4C9A-BC92-EDABC5F4A9A5 Q26865892-5F4EC091-CFB3-42D1-868F-43089F13A007 Q26995483-2B33AFB8-BC02-404A-9C27-C4C55907A0ED Q27007078-ADB93125-CF1C-447F-8673-A4BEB0EDA359 Q27303769-74C916F0-1950-483A-A2F2-FBD1B75505C0 Q27316453-013755C9-8F03-4FD4-BF37-3F54FB610DDC Q27497796-D3BBC2DF-C89E-4BDC-AF4F-8F356A804D22 Q28074099-0469D442-BA4B-4FA7-9FC4-343EEA917C11 Q28086874-76B5B7A9-330B-4B57-9742-6B8044FFCE96 Q28259238-AFEFC4E6-A699-41CA-8321-A7A982F45A02 Q28397818-54DE3BEE-C4A4-44B0-BBFA-43AEEFEE190D Q28567803-A637378C-7EF8-4326-8E56-19AE4BC46F57 Q30276375-08A9BDCF-3D46-40AD-BD7D-D40FC9DC2699 Q30360306-C3B346AC-4DC7-407A-ACBA-FDE5DCC7E62E Q30411278-CAD2AD5A-7C99-48A6-AB94-0D8D2B36DBF5 Q33624540-00FA8F22-8FCB-457F-B0CA-714B2A06BFED Q33797137-7C061DF3-3770-497D-B24F-F3CC688A6C83 Q33834046-D925B087-E0DD-4CA2-BC01-075A1B3E0790 Q34002086-44FEC543-3973-4A20-9750-4ACF6CD88823 Q34019783-F389DCBF-949D-45E7-BF38-6E2E7D2B8A44 Q34946464-9FDB28E5-8AB0-47C0-9292-C89EC3B97163 Q34998538-A178A908-9848-4A2F-8366-82F292A39C47 Q35019131-A164AB40-7AD5-412B-A6F4-45A51072AD8E Q35064995-EAB8F181-B769-4389-81DF-75B019761A85 Q35650827-73D24108-92CA-4DDB-BFF1-6BDEFED78B2A Q35808359-0CCDAAC2-FDFD-407C-8F24-24EBE6D3190F Q35810427-77C2C7C7-7A56-4BED-9A6B-620A76BAC1C7 Q35978959-03C3288B-0CDA-4067-AA31-8E690EB83C76 Q36020203-0049C4E7-FA4E-46A2-A763-BBCE8F0A9A61 Q36121992-12295A94-5F4C-4723-806A-470C0984B82E Q36188164-9887E2DF-AC3A-4C04-B643-4A504EF9BAEF Q36195292-2B9989EB-A50A-45FF-A6F3-CD8B171C3852 Q36268050-0C9997B4-9FB9-465A-97D5-879F57E2A0CF Q36271043-3C6CAE89-18DE-45A2-9247-88965EC19EB9 Q36348184-41D91575-F71E-4459-B056-DB349110C423

P2860

CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease.

http://www.wikidata.org/entity/Q35213298

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

CX3CR1 protein signaling modul ...... se model of Alzheimer disease.

@ast

CX3CR1 protein signaling modul ...... se model of Alzheimer disease.

@en

type

label

CX3CR1 protein signaling modul ...... se model of Alzheimer disease.

@ast

CX3CR1 protein signaling modul ...... se model of Alzheimer disease.

@en

prefLabel

CX3CR1 protein signaling modul ...... se model of Alzheimer disease.

@ast

CX3CR1 protein signaling modul ...... se model of Alzheimer disease.

@en

P1433

Q35213298-831DC328-6F7A-4EC8-B2B8-FA10E7757125

P1476

Q35213298-2D57EBA1-9F2D-4BD1-9F10-29B2D7567122

P2093

Q35213298-22C46001-7F58-4AE3-8585-CD037874CD0D

Q35213298-787215A5-5A08-4925-9FD4-2864D2D89719

Q35213298-888F1F05-764B-47E1-BE1F-ACA535AFA5D0

Q35213298-918BB443-D26F-4BD4-90D6-B82B8A41D7D1

Q35213298-9DFE8409-482A-4E03-8BAD-33478D1CE7F8

P2860

Q35213298-03B98B75-43DE-4073-A711-21B7C06B95A2

Q35213298-0B2B0567-CBF0-45E1-8660-788E6FE48278

Q35213298-0CEBCB4D-00F8-4372-A55C-9011C307C318

Q35213298-10289B9E-8B88-4F0A-B44E-4D80DC5A8175

Q35213298-121A7F33-595D-4F9C-95CB-910B0A42D103

Q35213298-1976AB4F-68B2-445E-84BF-178EE462DD0D

Q35213298-1AED0805-E77E-4C28-B634-CFF2D9CDA126

Q35213298-1D6CAB1C-A826-425E-BADB-5FE2A0DB5C85

Q35213298-28798DED-B868-4D78-9C3D-34632ADE8A03

Q35213298-32222582-3A71-4C06-99B1-4A21CCD6AC35

P304

Q35213298-9ECE8F1B-F6AA-4D0F-B951-687063E73ABB

P31

Q35213298-26796F93-7F43-4F86-855C-123EADD285CB

P356

Q35213298-6E6FABD9-2885-4C58-ADA1-FCB8ACAC8670

P407

Q35213298-AF96CE7B-F6DF-4F1E-8827-B8A46F3D390F

P433

Q35213298-B7F3D6D9-860C-40AB-83B8-1DCD87871286

P478

Q35213298-D3864F65-2F7C-45E4-B0EA-0C486A7D7FB5

P50

Q35213298-24AEBA80-D046-468F-8841-8FB28177F37F

Q35213298-E1DEDE5B-33D5-49E7-9563-3E572DF0144F

Q35213298-F5054306-4517-45BB-926B-F1E891DCC78B

P577

Q35213298-37708D20-D97E-4062-9C09-4D2A9AD5D6C0

P698

Q35213298-1D16942C-5164-42A7-AA8B-554737C84F77

P921

Q35213298-34A5103E-BCEF-498B-B454-E111FB5EAA2D

Q35213298-F1721A0F-84F7-4616-961D-596A16FBFAE1

P932

Q35213298-945E173B-E71B-4D58-9951-90A12A5A57AC

P356

JBC.M111.254268

P1433

Journal of Biological Chemistry

P1476

CX3CR1 protein signaling modul ...... use model of Alzheimer disease

@en

P2093

Brian Halabisky

http://www.w3.org/2001/XMLSchema#string

Li Gan

http://www.w3.org/2001/XMLSchema#string

Richard M Ransohoff

http://www.w3.org/2001/XMLSchema#string

Seo-Hyun Cho

http://www.w3.org/2001/XMLSchema#string

Yungui Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion

Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior.

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival

Does neuroinflammation fan the flame in neurodegenerative diseases?

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model

Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1)

Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1

Control of microglial neurotoxicity by the fractalkine receptor

Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation

P304

32713-32722

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M111.254268

http://www.w3.org/2001/XMLSchema#string

P407

P433

37

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P50

Tiina M. Kauppinen

P577

2011-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21771791

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3173153

http://www.w3.org/2001/XMLSchema#string